Filing Details
- Accession Number:
- 0000899243-21-042947
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-03 21:46:04
- Reporting Period:
- 2021-11-01
- Accepted Time:
- 2021-11-03 21:46:04
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1655759 | Arvinas Inc. | ARVN | Pharmaceutical Preparations (2834) | 472566120 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1753537 | G John Houston | C/O Arvinas, Inc. 5 Science Park, 395 Winchester Ave. New Haven CT 06511 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-11-01 | 40,000 | $16.00 | 872,333 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-11-01 | 8,513 | $87.13 | 863,820 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-01 | 15,918 | $87.98 | 847,902 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-01 | 15,569 | $88.86 | 832,333 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-11-01 | 40,000 | $0.00 | 40,000 | $16.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2028-09-25 | No | 4 | M | Direct |
Footnotes
- The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.4600 to $87.4500, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (3).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.4700 to $88.4600, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.4700 to $89.4500, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range within the range set forth in this footnote (5).
- This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 5, 2018, with the remainder of the shares vesting in equal monthly installments following January 5, 2018 through January 5, 2021.
Billionaire Hedge Funds
